Investigating the role of WASp signaling in aggressive T-cell lymphomas
WASp signaling in T-cell lymphomas
This study is looking at how a protein called WASp affects the growth of aggressive T-cell lymphomas, which are tough cancers to treat, by using special mice and data from real patients to find out how this protein helps tumors grow and survive, with the hope of discovering new ways to track the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-10945084 on NIH RePORTER |
What this research studies
This research focuses on understanding how the Wiskott-Aldrich syndrome protein (WASp) influences the development and growth of peripheral T-cell lymphomas (PTCL), which are aggressive cancers with poor survival rates. By utilizing a genetically engineered mouse model and analyzing clinical data from over 100 T-cell lymphoma cases, the study aims to uncover the mechanisms by which WASp contributes to tumor growth and survival. The research will explore the actin cytoskeleton's role in T-cell lymphoma biology and identify potential biomarkers for disease progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with peripheral T-cell lymphomas who may benefit from novel treatment strategies.
Not a fit: Patients with other types of lymphomas or non-cancerous conditions are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic targets and improved outcomes for patients with T-cell lymphomas.
How similar studies have performed: Previous research has shown promising results in targeting actin-related proteins in cancer therapies, suggesting potential for success in this approach.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Murga-Zamalloa, Carlos a. — University of Illinois at Chicago
- Study coordinator: Murga-Zamalloa, Carlos a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.